TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6829920
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia (controlled ventilation with N2O‐O2, intravenous fentanyl and pancuronium bromide; narcotic analgesics intramuscularly on demand postoperatively)
Study: 29676480
Drug: Medication compliance
Normalized name: ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Medication compliance and insight into schizophrenia
Study: 29676480
Drug: Expert witness
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expert witness explanation regarding medication compliance and insight
Study: 23771784
Drug: Subcutaneous insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous insulin algorithm
Study: 18036719
Drug: Dutasteride 0.5mg
Normalized name: DUTASTERIDE 0.5MG CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride 0.5mg daily
Study: 16650232
Drug: Albendazole single
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole single dose (400 mg)
Study: 16650232
Drug: Albendazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (400 mg for 3 days)
Study: 16650232
Drug: 1% permethrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% permethrin + albendazole single dose (400 mg)
Study: 16650232
Drug: 1% permethrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% permethrin + albendazole (400 mg for 3 days)
Study: 10961748
Drug: Senna compound
Normalized name: senna compounding powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Senna compound
Study: 9124864
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of pefloxacin twice daily for 5 days (group A)
Study: 9124864
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of pefloxacin twice daily for 7 days (group B)
Study: 29237339
Drug: Rhythm-and-music-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhythm-and-music-based therapy (R-MT), n=37
Study: 29237339
Drug: Horse-riding therapy
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Horse-riding therapy (H-RT), n=37
Study: 29237339
Drug: Rhythm-and-music-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhythm-and-music-based therapy (R-MT) and Horse-riding therapy (H-RT)
Study: 22784835
Drug: 52 mg
Normalized name: papain 52 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 52 mg hydrated implant
Study: 22784835
Drug: 84 mg
Normalized name: silymarin 84 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 84 mg hydrated implant
Study: 22784835
Drug: 84 mg
Normalized name: silymarin 84 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 84 mg nonhydrated implant
Study: 21167080
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment with sarpogrelate (300 mg/day)
Study: 21167080
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment without sarpogrelate
Study: 17435520
Drug: Corneal Refractive
Normalized name: hyaluronic acid Ophthalmic Gel [Optimend Corneal Repair]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corneal Refractive Therapy (CRTH) lens (Dk = 100)
Study: 15616299
Drug: Tigecycline single-dose
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tigecycline single-dose (12.5 to 300 mg)
Study: 15616299
Drug: Tigecycline multiple-dose
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tigecycline multiple-dose (25 to 100 mg every 12 h)
Study: 15616299
Drug: Tigecycline variable
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tigecycline variable volume and infusion rate (100 mg loading dose, followed by 50 mg every 12 h for 5 days)
Study: 11122886
Drug: High-dose pulse
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose pulse therapy with 13-cis-retinoic acid (13-cis-RA) after intensive chemoradiotherapy
Study: 17173588
Drug: Erbium:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erbium:YAG laser plus topical 5-flurouracil
Study: 15248876
Drug: Both IMZ
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both IMZ and Brånemark implants
Study: 9114824
Drug: Experimental agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental agents (other interferons, methotrexate, linomide, monoclonal antibodies, T‐cell receptor peptides, 2‐chlorodeoxyadenosine)
Study: 18221251
Drug: Fructose (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructose (40 g, 12% solution)
Study: 18221251
Drug: High fructose
Normalized name: High Fructose Corn Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fructose corn syrup (HFCS)
Study: 20877359
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with CA 19-9 monitoring
Study: 9935257
Drug: Alatrofloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alatrofloxacin (200 mg intravenous)
Study: 9935257
Drug: Cefotetan (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotetan (2 g intravenous)
Study: 8148278
Drug: Doxycycline 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 0.1 g twice daily
Study: 8148278
Drug: Lymecycline 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymecycline 0.6 g twice daily
Study: 3130927
Drug: Chloroquine phosphate
Normalized name: Chloroquine Phosphate
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine phosphate 500 mg weekly with proguanil hydrochloride 200 mg daily
Study: 3130927
Drug: Chloroquine 500
Normalized name: chloroquine 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine 500 mg weekly with sulfadoxine 500 mg‐pyrimethamine 25 mg weekly
Study: 24633823
Drug: Clopidogrel plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel plus unfractionated heparin
Study: 20975054
Drug: Extended-release melatonin
Normalized name: melatonin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release melatonin (Circadin®) at a dose of 2 mg 1 hour before bedtime for 8 weeks
Study: 19006470
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g of omega-3-acid ethyl esters (P-OM3) with 80 mg atorvastatin daily
Study: 12548212
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol (20 microg every 2 hours, increased to 40 microg depending on uterine contractions)
Study: 12548212
Drug: Vaginal dinoprostone
Normalized name: dinoprostone Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal dinoprostone (2 mg twice, 6 hours apart)
Study: 8561069
Drug: n-3 fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 fatty acids (2.5 g/d for 2 months)
Study: 1652597
Drug: Combined estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined estrogen and progestin (conjugated equine estrogens, 2.5 mg/day and medroxyprogesterone acetate, 60 mg/day)
Study: 1652597
Drug: Estrogen (conjugated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen (conjugated equine estrogens, 2.5 mg/day)
Study: 1652597
Drug: Progestin (medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progestin (medroxyprogesterone acetate, 60 mg/day)
Study: 22922768
Drug: Broncho‐Vaxom (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broncho‐Vaxom (7 mg daily for the first 10 days of each month for 3 months)
Study: 22922768
Drug: Corticosteroid and/or
Normalized name: Corticosteroid and/or corticosteroid derivative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid and/or immunosuppressive therapy (control group)
Study: 16394405
Drug: Formulation C
Normalized name: Army Liposome Formulation component monophosphoryl lipid A
DrugBank: Monophosphoryl lipid A (DB19290)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation C (mometasone furoate)
Study: 16394405
Drug: Formulation A
Normalized name: meningococcal vaccine of unknown formulation and unknown serogroups
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation A (mometasone furoate)
Study: 16394405
Drug: Formulation D
Normalized name: Complete Formulation D3000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation D (mometasone furoate)
Study: 10767241
Drug: Oral appliances
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral appliances with 2-mm mandibular advancement
Study: 10767241
Drug: Oral appliances
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral appliances with 4-mm mandibular advancement
Study: 10767241
Drug: Oral appliances
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral appliances with 6-mm mandibular advancement
Study: 10767241
Drug: Oral appliances
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral appliances (all advancements)
Study: 9130733
Drug: GnRH-a plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH-a plus EE-CPA pill
Study: 9130733
Drug: EE-CPA pill
Normalized name: norgestimate
DrugBank: Norgestimate (DB00957)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EE-CPA pill alone
Study: 8452318
Drug: Intranasal budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intranasal budesonide as dry powder (400 micrograms daily, one inhalation/nostril/day)
Study: 8452318
Drug: Intranasal budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intranasal budesonide as aerosol (400 micrograms daily, two puffs/nostril/day)
Study: 8452318
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not applicable, both groups received active treatment)
Study: 26795282
Drug: efavirenz, maraviroc
Approvals — FDA: no, EMA: no, PMDA: no
Description: efavirenz, maraviroc or maraviroc+raltegravir with fixed-dose tenofovir disoproxil fumarate/emtricitabine
Study: 24532547
Drug: Nebivolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol (5 mg once daily for 8 days)
Study: 24532547
Drug: Placebo (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (once daily for 8 days)
Study: 278459
Drug: Atropine 0.0075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 0.0075 mg/kg
Study: 8109230
Drug: Atropine 0.02
Normalized name: ATROPINE 0.025/DIFENOXIN 1MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 0.02 mg/kg
Study: 278459
Drug: Atropine 0.01
Normalized name: atropine 0.0194 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 0.01 mg/kg to 0.02 mg/kg
Study: 29938420
Drug: Intramuscular 17‐alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular 17‐alpha hydroxyprogesterone
Study: 29938420
Drug: Intramuscular Neurobion
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular Neurobion
Study: 22717414
Drug: Ringer lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer lactate solution at 240 mL per hour (group 4)
Study: 22717414
Drug: No intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intravenous hydration (group 1)
Study: 22717414
Drug: Ringer lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer lactate solution (any group)
Study: 20393152
Drug: Insulin resistance
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin resistance (homeostasis model assessment index)
Study: 18499399
Drug: ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ferrous sulfate (200 mg twice a day, corresponding to 80 mg of elemental iron)
Study: 18499399
Drug: ferrous glycinate
Normalized name: Ferrous cysteine glycinate
DrugBank: Ferrous cysteine glycinate (DB11197)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ferrous glycinate chelate (250 mg/d, corresponding to 50 mg of elemental iron)
Study: 15925562
Drug: Celacade (immune
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celacade (immune modulation therapy)
Study: 7733032
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of vitamin A
Study: 18762597
Drug: Standard medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medication counseling
Study: 25604346
Drug: Bromelain (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromelain (1000 mg·day(‐1))
Study: 17352404
Drug: Tobramycin inhalation
Normalized name: Tobramycin Inhalation Powder
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin inhalation powder (TIP), 4 capsules of 28 mg (total 112 mg)
Study: 17352404
Drug: Tobramycin solution
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin solution for inhalation (TSI), 300 mg
Study: 16286669
Drug: EVA (560
Approvals — FDA: no, EMA: no, PMDA: no
Description: EVA (560 mg/d)
Study: 7622632
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene and scaling
Study: 7622632
Drug: Full initial
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Full initial therapy including root planning
Study: 2645848
Drug: Dextroamphetamine sulfate
Normalized name: Dextroamphetamine Sulfate
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine sulfate (0.5 mg/kg/d)
Study: 2645848
Drug: Fenfluramine hydrochloride
Normalized name: fenfluramine hydrochloride
DrugBank: Fenfluramine (DB00574)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenfluramine hydrochloride (0.6 mg/kg/d increased to 2.0 mg/kg/d)
Study: 353461
Drug: Stenoptin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stenoptin (1 tablet 3 times per day for 8 weeks, then reduced to 1 tablet twice per day)
Study: 353461
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 tablet 3 times per day for 8 weeks, then reduced to 1 tablet twice per day)
Study: 28155333
Drug: Zofenopril 30-60
Normalized name: zofenopril 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zofenopril 30-60 mg daily
Study: 28155333
Drug: Lisinopril 5-10
Normalized name: lisinopril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 5-10 mg daily
Study: 21793387
Drug: Jin's 'Sanzhen'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jin's 'Sanzhen' therapy
Study: 21793387
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Jin's 'Sanzhen' therapy and rehabilitation training
Study: 10795118
Drug: epirubicin 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: epirubicin 90 mg/m2-paclitaxel 175 mg/m2; 4 cycles bi-weekly, supported by G-CSF 5 micrograms/kg day 5-13 and 3 sequential cycles of CMF 600/40/600 mg/m2 at 2-weeks interval
Study: 10795118
Drug: epirubicin 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: epirubicin 90 mg/m2-cyclophosphamide 600 mg/m2; 4 cycles tri-weekly, and 3 sequential cycles of CMF 600/40/600 mg/m2 at 3-weeks interval
Study: 1549937
Drug: oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral clonidine 300 micrograms 120 min before surgery
Study: 1549937
Drug: oral diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral diazepam 0.15 mg/kg 120 min before surgery
Study: 29232560
Drug: Intravenous tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tranexamic acid (TXA) 1 g administered preoperatively
Study: 29232560
Drug: Intravenous tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tranexamic acid (TXA) 1 g administered preoperatively in women
Study: 29232560
Drug: Intravenous tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tranexamic acid (TXA) 1 g administered preoperatively in men
Study: 21196081
Drug: Substance abuse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substance abuse treatment initiation and engagement
Study: 21196081
Drug: Substance abuse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substance abuse treatment engagement
Study: 18958548
Drug: Group H
Normalized name: Prostaglandin group H
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group H (prednisolone > or =10,000 mg)
Study: 18958548
Drug: Group L
Normalized name: Blood group Lewis alpha-4-fucosyltransferase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group L (prednisolone <10,000 mg)
Study: 1576099
Drug: nifedipine-SR (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: nifedipine-SR (10 mg b.i.d)
Study: 31097338
Drug: 20% albumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% albumin fluid bolus therapy
Study: 31097338
Drug: Crystalloid fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystalloid fluid bolus therapy
Study: 30315670
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day of DHEA for 28 days
Study: 30315670
Drug: DHEA administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA administration
Study: 22177821
Drug: Propofol-saline solution
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol-saline solution admixture (Group A - Control)
Study: 20451469
Drug: Changes in
Normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Changes in neurotransmitters and biological response modifiers
Study: 12818953
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg intranasal hydromorphone hydrochloride
Study: 12818953
Drug: 2.0 mg
Normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg intranasal hydromorphone hydrochloride
Study: 12818953
Drug: 2.0 mg
Normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg intravenous hydromorphone hydrochloride
Study: 7960542
Drug: Nd-Yag laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nd-Yag laser treatment
Study: 7960542
Drug: Nd-Yag laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nd-Yag laser treatment combined with transurethral resection (TUR)
Study: 29705707
Drug: Alcohol at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol at 60 mg/dL
Study: 8157042
Drug: Intranasal glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intranasal glucagon (2 mg)
Study: 26884472
Drug: Intramuscular glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intramuscular glucagon (weight-based dose)
Study: 26884472
Drug: Intranasal glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intranasal glucagon (2 mg and 3 mg)
Study: 27403406
Drug: Dexamethasone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (4 mg/mL), administered via intratympanic injection, 0.5 ml, once every 2 days for 3 times
Study: 27403406
Drug: Methylprednisolone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (40 mg/mg), administered via intratympanic injection, 0.5 ml, along with bicarbonate
Study: 22833175
Drug: Selective head-cooling
Normalized name: Head & Shoulders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective head-cooling treatment (therapeutic hypothermia)
Study: 22833175
Drug: Control (rectal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (rectal temperature 37°C)
Study: 16759927
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone patches (300 microg T daily)
Study: 15025600
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg kg(‐1) of aminophylline
Study: 11708704
Drug: Creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine monohydrate (20 g per day for 6 days)
Study: 10380782
Drug: Perfume exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perfume exposure during eye exposure (with fresh air inhaled)
Study: 28333318
Drug: Oral dydrogesterone
Normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dydrogesterone 30 mg daily (10 mg three times daily)
Study: 28333318
Drug: Micronized vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized vaginal progesterone (MVP) 600 mg daily (200 mg three times daily)
Study: 23039088
Drug: Topiramate (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (100 mg twice daily)
Study: 26035251
Drug: Nitroprusside administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroprusside administration
Study: 3492950
Drug: Trimethoprim-sulfamethoxazole, 320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole, 320 mg/d-1600 mg/d for 2 or 6 weeks
Study: 3492950
Drug: Ampicillin, 2
Normalized name: Ampicillin, 250 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin, 2 g/d for 2 or 6 weeks
Study: 24973959
Drug: Afatinib (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib (40 mg once daily)
Study: 24973959
Drug: Methotrexate (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (40 mg/m2 once weekly)
Study: 12615792
Drug: Azimilide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azimilide (100 to 125 mg once daily for 6 or 9 months)
Study: 10228046
Drug: rhumAb-E25 infusions
Normalized name: RHUMAB-E25
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: rhumAb-E25 infusions biweekly for 46 weeks
Study: 10228046
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of rhumAb-E25 infusions
Study: 31202210
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy combined with cryotherapy (MT-C)
Study: 28644246
Drug: In-hospital exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-hospital exercise intervention during neoadjuvant chemotherapy
Study: 24474552
Drug: Red Bull
Normalized name: acid red 35
DrugBank: Pantothenic acid (DB01783)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red Bull (355 mL)